Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics
© 2024 The Authors..
Urothelial carcinoma in situ (CIS) is an aggressive phenotype of non-muscle-invasive bladder cancer. Molecular features unique to CIS compared to high-grade papillary tumors are underexplored. RNA sequencing of CIS, papillary tumors, and normal urothelium showed lower immune marker expression in CIS compared to papillary tumors. We identified a 46-gene expression signature in CIS samples including selectively upregulated known druggable targets MTOR, TYK2, AXIN1, CPT1B, GAK, and PIEZO1 and selectively downregulated BRD2 and NDUFB2. High expression of selected genes was significantly associated with CIS in an independent dataset. Mutation analysis of matched CIS and papillary tumors revealed shared mutations between samples across time points and mutational heterogeneity. CCDC138 was the most frequently mutated gene in CIS. The immunological landscape showed higher levels of PD-1-positive cells in CIS lesions compared to papillary tumors. We identified CIS lesions to have distinct characteristics compared to papillary tumors potentially contributing to the aggressive phenotype.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
iScience - 27(2024), 3 vom: 15. März, Seite 109179 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anurag, Meenakshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 06.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2024.109179 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369298179 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369298179 | ||
| 003 | DE-627 | ||
| 005 | 20240306233255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2024.109179 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369298179 | ||
| 035 | |a (NLM)38439961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Anurag, Meenakshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Urothelial carcinoma in situ (CIS) is an aggressive phenotype of non-muscle-invasive bladder cancer. Molecular features unique to CIS compared to high-grade papillary tumors are underexplored. RNA sequencing of CIS, papillary tumors, and normal urothelium showed lower immune marker expression in CIS compared to papillary tumors. We identified a 46-gene expression signature in CIS samples including selectively upregulated known druggable targets MTOR, TYK2, AXIN1, CPT1B, GAK, and PIEZO1 and selectively downregulated BRD2 and NDUFB2. High expression of selected genes was significantly associated with CIS in an independent dataset. Mutation analysis of matched CIS and papillary tumors revealed shared mutations between samples across time points and mutational heterogeneity. CCDC138 was the most frequently mutated gene in CIS. The immunological landscape showed higher levels of PD-1-positive cells in CIS lesions compared to papillary tumors. We identified CIS lesions to have distinct characteristics compared to papillary tumors potentially contributing to the aggressive phenotype | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Omics | |
| 700 | 1 | |a Strandgaard, Trine |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sung Han |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Yongchao |e verfasserin |4 aut | |
| 700 | 1 | |a Comperat, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ahmadie, Hikmat |e verfasserin |4 aut | |
| 700 | 1 | |a Inman, Brant A |e verfasserin |4 aut | |
| 700 | 1 | |a Taber, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Nordentoft, Iver |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Jørgen Bjerggaard |e verfasserin |4 aut | |
| 700 | 1 | |a Dyrskjøt, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Lerner, Seth P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 27(2024), 3 vom: 15. März, Seite 109179 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:3 |g day:15 |g month:03 |g pages:109179 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2024.109179 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 3 |b 15 |c 03 |h 109179 | ||